BACKGROUND: HER2, which is overexpressed in 25-30% of human breast cancers, is a tyrosine kinase receptor critical for the signal transduction network that regulates proliferation, migration and apoptosis of cells. METHOD: We report the effects of two novel HER2-binding affibody molecules (Affibody), (ZHER2:4)2 and ZHER2:342, on intracellular signal transduction pathways (Erk1/2, Akt and PLCgamma1) using quantitative immunoblotting techniques and their biological effects in cell culture. The clinically approved antibody trastuzumab (Herceptin) was used as reference substance. RESULTS: Our data showed that, although all substances target HER2, the effects on the receptor and signaling molecules differed. For example, HER2 phosphorylation was induced by trastuzumab and (ZHER2:4)2 but inhibited by ZHER2:342. The effects these substances had on signal transduction correlated to some degree with changes in growth and migration, e.g. (ZHER2:4)2 stimulated phosphorylation of Erk1/2 and PLCgamma1, as well as growth and migration, while ZHER2:342 did not. ZHER2:342 even inhibited phosphorylation of PLCgamma1 and migration. CONCLUSION: Our data suggest that ZHER2:342 is a promising small agent (7 kDa) that may be used as an alternative, or complement, to trastuzumab. If radiolabelled, it can hopefully also be used for HER2 imaging and radionuclide therapy. Copyright 2006 S. Karger AG, Basel.
BACKGROUND:HER2, which is overexpressed in 25-30% of humanbreast cancers, is a tyrosine kinase receptor critical for the signal transduction network that regulates proliferation, migration and apoptosis of cells. METHOD: We report the effects of two novel HER2-binding affibody molecules (Affibody), (ZHER2:4)2 and ZHER2:342, on intracellular signal transduction pathways (Erk1/2, Akt and PLCgamma1) using quantitative immunoblotting techniques and their biological effects in cell culture. The clinically approved antibody trastuzumab (Herceptin) was used as reference substance. RESULTS: Our data showed that, although all substances target HER2, the effects on the receptor and signaling molecules differed. For example, HER2 phosphorylation was induced by trastuzumab and (ZHER2:4)2 but inhibited by ZHER2:342. The effects these substances had on signal transduction correlated to some degree with changes in growth and migration, e.g. (ZHER2:4)2 stimulated phosphorylation of Erk1/2 and PLCgamma1, as well as growth and migration, while ZHER2:342 did not. ZHER2:342 even inhibited phosphorylation of PLCgamma1 and migration. CONCLUSION: Our data suggest that ZHER2:342 is a promising small agent (7 kDa) that may be used as an alternative, or complement, to trastuzumab. If radiolabelled, it can hopefully also be used for HER2 imaging and radionuclide therapy. Copyright 2006 S. Karger AG, Basel.
Authors: Zhen Cheng; Omayra Padilla De Jesus; Daniel J Kramer; Abhijit De; Jack M Webster; Olivier Gheysens; Jelena Levi; Mohammad Namavari; Sen Wang; Jinha Mark Park; Rong Zhang; Hongguang Liu; Brian Lee; Faisal A Syud; Sanjiv Sam Gambhir Journal: Mol Imaging Biol Date: 2009-09-25 Impact factor: 3.488
Authors: Sang Bong Lee; Moinuddin Hassan; Robert Fisher; Oleg Chertov; Victor Chernomordik; Gabriela Kramer-Marek; Amir Gandjbakhche; Jacek Capala Journal: Clin Cancer Res Date: 2008-06-15 Impact factor: 12.531
Authors: Lovisa Göstring; Magdalena Malm; Ingmarie Höidén-Guthenberg; Fredrik Y Frejd; Stefan Ståhl; John Löfblom; Lars Gedda Journal: PLoS One Date: 2012-06-29 Impact factor: 3.240